MD Becker Partners' newsletter covering the life science industry
The 2010 BMT Tandem Meetings were held in Orlando, Florida this past week [February 24-28, 2010]. Considered the premier event for hematopoietic cell transplantation [HCT] and cellular therapy, the annual event attracts more than 2,500 clinicians, transplant nurses, clinical research professionals, data managers, pharmacists, center administrators and mid-level practitioners. With more than 200 abstracts being [...]
* MD Becker Partners reporting live from the JP Morgan Healthcare Conference This week, nearly 6,500 registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference to hear 25-minute presentations from 338 life science companies. For industry executives and investors, the annual event serves as a good barometer for the rest of the [...]
On the heels of the Dow Jones Industrial Average (DJIA) logging its worst annual performance since 1931 and the NASDAQ Composite (COMP) having its worst year since inception in 1971, it may have seemed counter intuitive to provide a bullish outlook for the biotechnology industry in 2009. Nonetheless, at the start of the year we [...]
In September 2009, Osiris Therapeutics, Inc. (OSIR) reported preliminary results from two Phase III trials evaluating its Prochymal product candidate for the treatment of acute Graft-versus-Host disease [GVHD]. Unfortunately, neither trial reached its primary endpoint, sending shares from $14 to a 52-week low of $5.35 by November 2009. The results were the latest in a [...]
Follow MD Becker Partners